Informations générales (source: ClinicalTrials.gov)
Disease Registry on Patients With Advanced NSCLC Harboring METex14 Skipping Alterations (MOMENT)
Observational
EMD Serono Research & Development Institute, Inc. (Voir sur ClinicalTrials)
octobre 2022
mars 2027
21 septembre 2024
The purpose of this multi-national disease registry is to collect prospectively (with
longitudinal follow-up) high-quality, standardized, and contemporaneous data to capture
changes in the non-small cell lung cancer (NSCLC) treatment landscape and outcomes over
time.
The registry will capture data on participants; demographic, clinical characteristics
(including biomarker data), treatment patterns, and effectiveness and safety outcomes for
advanced NSCLC with mesenchymal-epithelial transition exon 14 (METex14) participants
treated with systemic therapy.
Etablissements
| Les établissements d'Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| AP-HP - Hôpital Tenon | Contact (sur clinicalTrials) | ||||
| CLCC INSTITUT CURIE | Contact (sur clinicalTrials) | ||||
| Les établissements sans correspondance certaine dans le répertoire FINESS dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
| Centre Hospitalier de Cholet - Cholet - France | Contact (sur clinicalTrials) | ||||
| Centre Leon Berard - Lyon Cedex 08 - France | Contact (sur clinicalTrials) | ||||
| CHRU Lille - Lille cedex - France | Contact (sur clinicalTrials) | ||||
| CHU de Toulouse Hopital Larrey - Toulouse - France | Contact (sur clinicalTrials) | ||||
| Hôpital du Scorff - Lorient - France | Contact (sur clinicalTrials) | ||||
Critères
Tous
Inclusion Criteria:
- Participants who signed ICF
- Participants with advanced stage (stages IIIB-IV) NSCLC (all histologies) and
Confirmed METex14 skipping alterations (by valid assay)
- Participants who are starting or are already being treated with systemic therapy
- Participants who signed ICF
- Participants with advanced stage (stages IIIB-IV) NSCLC (all histologies) and
Confirmed METex14 skipping alterations (by valid assay)
- Participants who are starting or are already being treated with systemic therapy
- Participants who are enrolled in a clinical trial